A continuation of Parts 1 and 2.

Listen in as Thayer explains how underlying infections are the predominant issue with chronically infected Lyme/MSIDS patients and that the moniker of PTLDS hurts patients as it denies persistent infection, thereby denying patients crucial anti-microbial treatment.  She also delineates why this is happening in the research world (researchers follow the money as they need grants) and how only going down the PTLDS road will affect insurance as well as treatment.

I’m thankful that Thayer clearly states Lyme groups should not be in support of any research using the PTLDS moniker.  I completely agree.  Until patients speak up on this point, damaging research – ignoring the root issue will continue to be done and important monies used up.  The same thing should be said about climate data as well.

%d bloggers like this: